Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial-Reference-Cited by-同舟云学术

Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial

Published:2016-12-22 Issue:3 Volume:161 Page:473-482
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Yamamoto Daigo,Sato Nobuaki,Rai Yoshiaki,Yamamoto Yutaka,Saito Mitsue,Iwata Hiroji,Masuda Norikazu,Oura Shoji,Watanabe Junichiro,Hattori Satoshi,Matsuura Yoshimasa,Kuroi Katsumasa

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-016-4075-6.pdf

Reference18 articles.

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30

2. De Angelis R, Sant M, Coleman MP, EUROCARE-5 Working Group et al (2014) Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol 15:23–34

3. Verma S, McLeod D, Batist G, Robidoux A, Martins IR, Mackey JR (2011) In the end what matters most? A review of clinical endpoints in advanced breast cancer. Oncologist 16:25–35

4. O’Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812–2823

5. Beslija S, Obralic N, Basic H et al (2006) Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression as first-line therapy for patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 24(18 suppl):571 (Abstract)

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Statistical Analysis Methods and Reporting of Patient-Reported Outcomes in Randomized Controlled Trials for Cancer Conducted in Japan: A Systematic Review;Cureus;2024-05-21

2. Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran;Archives of Iranian Medicine;2024-04-01

3. Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial;BMC Cancer;2022-12-28

4. Quality-of-life methodology in hormone receptor–positive advanced breast cancer: Current tools and perspectives for the future;Cancer Treatment Reviews;2022-01

5. Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review;Cancer Medicine;2020-05-26